Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.

PloS one - 1 Jan 2013

Kang Hyo Jeong, Chun Sung-Min, Kim Kyu-Rae, Sohn Insuk, Sung Chang Ohk

Abstract excerpt

PURPOSE: Inactivation of TP53, which occurs predominantly by missense mutations in exons 4-9, is a major genetic alteration in a subset of human cancer. In spite of growing evidence that gain-of-function (GOF) mutations of p53 also have oncogenic activity, little is known about the clinical relevance of these mutations. METHODS: The clinicopathological features of high-grade serous ovarian carcinoma (HGS-OvCa)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Composition
Share to Carcinoma
Share to CpG Islands

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Neoplasm Grading

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23967324
DOI: 10.1371/journal.pone.0072609
PMCID: PMC3742716

Genes

HGS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.PMID 23967324Read ↗

TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.Semantic proximity Read ↗

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized TherapeuticsSemantic proximity Read ↗

TP53 mutations in epithelial ovarian cancerSemantic proximity Read ↗

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)Semantic proximity Read ↗

Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.Semantic proximity Read ↗

Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian CarcinomaSemantic proximity Read ↗

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.Semantic proximity Read ↗

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.Semantic proximity Read ↗

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesSemantic proximity Read ↗

The consequence of oncomorphic TP53 mutations in ovarian cancer.Semantic proximity Read ↗

Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer.Semantic proximity Read ↗

TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.